IA
PRVB

IndexIQ Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

IndexIQ Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-22,766
Closed -$386K – 1360
2020
Q4 		$386K Buy
22,766
+2,351
+12% +$35.2K 0.01% 509
2020
Q3 		$262K Buy
20,415
+1,106
+6% +$14K 0.01% 470
2020
Q2 		$272K Sell
19,309
-2,319
-11% -$29.3K 0.01% 361
2020
Q1 		$199K Buy
+21,628
New +$279K 0.01% 310

Other funds holding PRVB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

IndexIQ Advisors's PRVB Position: Q1 2021 in Review

IndexIQ Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2021, closing a stake of 22,766 shares — an estimated $386K sold.

IndexIQ Advisors first reported a position in PRVB in Q1 2020 and held it in 4 quarters. The position peaked at $386K in Q4 2020. 120 funds tracked by Wall St. Rank hold PRVB as of Q1 2021.

  • IndexIQ Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • IndexIQ Advisors sold 22,766 Provention Bio, Inc. Common Stock shares in Q1 2021, an estimated $386K.
  • IndexIQ Advisors first reported a position in Provention Bio, Inc. Common Stock in Q1 2020 and held it in 4 quarters.
  • IndexIQ Advisors's Provention Bio, Inc. Common Stock position peaked at $386K in Q4 2020.
  • 120 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2021.

Based on IndexIQ Advisors's 13F filing for Q1 2021, filed 7 May 2021.